Table 1 Current anti-VEGF agents on retinal diseases
From: Diabetic macular edema: new concepts in patho-physiology and treatment
Anti-VEGF agents | Mode of action | Molecular weight (kDa) | The phase III trail | Year approved by FDA |
|---|---|---|---|---|
Pegaptanib | 28-base ribonucleic aptamer | 50 | Vision trial | 2004 for wet AMD |
Ranibizumab (Lucentis, Genetech) | a monoclonal antibody fragment (Fab) derived from bevacizumab | 50 | Anchor, marina, pier (wet AMD) Ride/rice(DME) | 2006 approved by FDA for wet AMD 2012approved by FDA for diabetic macular edema |
Bevacizumab (Avastin, Genetech) | Humanized anti-VEGF mAb, specific against VEGF165. It was first used as an adjunct treatment for metastatic colon cancer | 149 | None for eye diseases | 2004 approved by FDA for colorectal cancer |
Aflibercept (Elya, (Regeneron Pharmaceuticals) VEGF-Trap | Recombinant VEGFR fusion protein that binds VEGFA and B,PGF | 115 | VIEW 1 and VIEW2 for wet AMD | 2011 approved by FDA for wet AMD 2012 European Medicines Agency approved for AMD |
KH902 (Chengdu Kanghong Biotechnology Co. Ltd) | A humanized fusion protein that binds all forms of VEGFA,VEGF receptor 1 and 2 and the Fc portion of IgG1 | 143 | Lamp, phoenix | 2013 approved by cFDA for wet AMD |